论文部分内容阅读
目的观察多虑平联合匹维溴胺治疗非便秘型肠易激综合征的疗效。方法将符合罗马Ⅲ诊断标准的92例非便秘型肠易激综合征患者随机分为两组,治疗组46例,予以多虑平12.5 mg、3次/d;匹维溴胺50 mg、3次/d口服:对照组46例,给予匹维溴胺50 mg、3次/d口服,疗程均为4周。观察患者腹痛、腹泻、腹部不适及排便次数和大便性状的改善情况。结果治疗组总有效率86.96%,对照组总有效率67.39%,两组比较差异有统计学意义(P<0.05)。结论多虑平匹维溴胺联合治疗非便秘型肠易激综合征疗效较好,不良反应小,不影响肝肾功能,患者易于接受。
Objective To observe the efficacy of doxepin combined with pirfenidol in the treatment of non-constipation-induced irritable bowel syndrome. Methods Ninety-two patients with non-constipation-predominant irritable bowel syndrome who met the diagnostic criteria of Rome Ⅲ were randomly divided into two groups. The treatment group received 46 doses of doxepin 12.5 mg three times daily, Oral / d oral: control group of 46 patients, given pivolvidine 50 mg, 3 times / d orally, the course of treatment were 4 weeks. Observe the patient’s abdominal pain, diarrhea, abdominal discomfort and defecation frequency and stool performance improvement. Results The total effective rate was 86.96% in the treatment group and 67.39% in the control group, with significant difference between the two groups (P <0.05). Conclusions Doxopinviru bromide combined treatment of non-constipation-predominant irritable bowel syndrome has good curative effect, small adverse reactions, does not affect liver and kidney function, patients are easy to accept.